bosutinib
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Cognitive Impairment
Conditions
Mild Cognitive Impairment, Dementia
Trial Timeline
Sep 1, 2016 → Dec 31, 2025
NCT ID
NCT02921477About bosutinib
bosutinib is a phase 1 stage product being developed by Pfizer for Mild Cognitive Impairment. The current trial status is unknown. This product is registered under clinical trial identifier NCT02921477. Target conditions include Mild Cognitive Impairment, Dementia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05363488 | Pre-clinical | Completed |
| NCT04258943 | Phase 1/2 | Active |
| NCT03128411 | Phase 2 | Completed |
| NCT02906696 | Phase 2 | Terminated |
| NCT02921477 | Phase 1 | UNKNOWN |
| NCT02546375 | Pre-clinical | Completed |
| NCT02501330 | Pre-clinical | Completed |
| NCT02228382 | Approved | Terminated |
| NCT01903733 | Pre-clinical | Completed |
| NCT01331291 | Phase 2 | Completed |
| NCT00759837 | Phase 1 | Completed |
| NCT00725426 | Phase 1 | Completed |
| NCT00261846 | Phase 2 | Completed |
Competing Products
20 competing products in Mild Cognitive Impairment